HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors with losses in excess of $100,000 to submit their losses now to learn if they qualify to recover compensable damages. Relevant Holding Period: Before Feb. 27, 2020Sign Up: www.hbsslaw.com/investor-fraud/SAGEContact An Attorney Now: SAGE@hbsslaw.com 844-916-0895 Sage Therapeutics, Inc. (SAGE) Investigation: The investigation centers on whether Sage misrepresented its flagship drugs, Zulresso and Zuranolone (SAGE-217). Zulresso, Sage’s lead product, was approved by the FDA in March 2019 to treat postpartum depression (PPD) and made commercially available in June 2019. In past quarters, Sage said it would take only 6-9 months for sites administering Zulresso to become treatment-ready. Zuranolone, Sage’s next generation drug, purportedly treats major depression disorder (MDD). The Company has characterized the drug as “a breakthrough therapy product” since i
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your RightsAccesswire
- Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGEAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEGlobeNewswire
- An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.Accesswire
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website